Scholarlink

Introduction <p>Fibrotic interstitial lung diseases are chronic diffuse parenchymal disorders characterised by progressive scarring and substantial morbidity. Transient elastography–derived liver stiffness is an established non-invasive marker of hepatic fibrosis, but it is unclear whether this liver-focused measurement carries any signal related to fibrotic interstitial lung disease. To assess, in a cross-sectional observational cohort, whether liver stiffness (LS) measured by transient elastography (TE) discriminates individuals with interstitial lung disease (ILD) from healthy controls and relates to HRCT-based disease burden, and to explore in-sample an empirical cut-point with pre-specified sensitivity analyses.</p> Methods <p>65 patients with ILD and 60 age- and sex-matched healthy controls underwent LS assessment using FibroScan<sup>®</sup>. LS values were compared with clinical parameters, radiological scores (Warrick Score and Early Decision Severity Score [EDSS]), and functional indices. Receiver operating characteristic (ROC) analysis determined the optimal LS cut-off for ILD prediction. Subgroup analyses compared connective tissue disease-related ILD (CTD-ILD) to non-CTD-ILD, and correlations between LS and demographic or disease-specific variables were examined.</p> Results <p>Median LS was significantly higher in ILD patients than in controls (4.90 vs. 2.98&#xa0;kPa; <i>p</i> &lt; 0.001). ROC analysis yielded an area under the curve of 0.867 for LS in predicting ILD, with a cut-off of 3.88&#xa0;kPa (sensitivity, 76.9%; specificity, 85.0%). Non-CTD-ILD patients exhibited greater LS than CTD-ILD patients (6.5 vs. 4.6&#xa0;kPa; <i>p</i> = 0.009). Within the CTD-ILD subgroup, only age correlated with LS (r = 0.402; <i>p</i> = 0.012). An LS ≥ 7.0&#xa0;kPa was associated with a usual interstitial pneumonia pattern in 72.2% of cases, and advanced fibrosis (F3) was more frequent in non-CTD-ILD (<i>p</i> = 0.023).</p> Conclusions <p>In this cross-sectional cohort, TE-derived liver stiffness shows in-sample discriminatory ability and aligns with HRCT involvement, indicating a candidate biomarker signal; prognostic use is unproven and warrants adequately powered longitudinal validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Increased transient elastography-derived liver stiffness in fibrotic interstitial lung disease compared with healthy controls and its association with high-resolution computed tomography extent: a cross-sectional observational study

  • 期刊论文

  • 发表日期：

    2025年12月19日

查看全文
  • Burak Okyar,
  • Servet Yüce,
  • Enes Karacan,
  • Fatih Necip Arıcı,
  • Alper Yıldırım,
  • Emrah Koç,
  • Zeynep Tüzün,
  • Sibel Kara,
  • Okan Dilek,
  • Hilmi Erdem Sümbül,
  • Emine Duygu Ersözlü

摘要

Introduction

Fibrotic interstitial lung diseases are chronic diffuse parenchymal disorders characterised by progressive scarring and substantial morbidity. Transient elastography–derived liver stiffness is an established non-invasive marker of hepatic fibrosis, but it is unclear whether this liver-focused measurement carries any signal related to fibrotic interstitial lung disease. To assess, in a cross-sectional observational cohort, whether liver stiffness (LS) measured by transient elastography (TE) discriminates individuals with interstitial lung disease (ILD) from healthy controls and relates to HRCT-based disease burden, and to explore in-sample an empirical cut-point with pre-specified sensitivity analyses.

Methods

65 patients with ILD and 60 age- and sex-matched healthy controls underwent LS assessment using FibroScan®. LS values were compared with clinical parameters, radiological scores (Warrick Score and Early Decision Severity Score [EDSS]), and functional indices. Receiver operating characteristic (ROC) analysis determined the optimal LS cut-off for ILD prediction. Subgroup analyses compared connective tissue disease-related ILD (CTD-ILD) to non-CTD-ILD, and correlations between LS and demographic or disease-specific variables were examined.

Results

Median LS was significantly higher in ILD patients than in controls (4.90 vs. 2.98 kPa; p < 0.001). ROC analysis yielded an area under the curve of 0.867 for LS in predicting ILD, with a cut-off of 3.88 kPa (sensitivity, 76.9%; specificity, 85.0%). Non-CTD-ILD patients exhibited greater LS than CTD-ILD patients (6.5 vs. 4.6 kPa; p = 0.009). Within the CTD-ILD subgroup, only age correlated with LS (r = 0.402; p = 0.012). An LS ≥ 7.0 kPa was associated with a usual interstitial pneumonia pattern in 72.2% of cases, and advanced fibrosis (F3) was more frequent in non-CTD-ILD (p = 0.023).

Conclusions

In this cross-sectional cohort, TE-derived liver stiffness shows in-sample discriminatory ability and aligns with HRCT involvement, indicating a candidate biomarker signal; prognostic use is unproven and warrants adequately powered longitudinal validation.